Sequence therapy in patients with metastatic renal cell carcinoma: Comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors

European Urology

Volumn 60, Issue 6, 2011, Pages 1163-1170

  Busch, Jonas ^a   Seidel, Christoph ^b   Kempkensteffen, Carsten ^a   Johannsen, Manfred ^a   Wolff, Ingmar ^a   Hinz, Stefan ^a   Magheli, Ahmed ^a   Miller, Kurt ^a   Grünwald, Viktor ^b   Weikert, Steffen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Metastasis; Progressive disease; Renal cell carcinoma; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; SORAFENIB; SUNITINIB;

ADULT; AGED; ANEMIA; ARTICLE; CACHEXIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ERUPTION; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; KIDNEY CARCINOMA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METASTASTIC RENAL CELL CARCINOMA; METASTATIC RENAL CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; STOMATITIS; STROKE; THROMBOSIS; TREATMENT RESPONSE;

ACADEMIC MEDICAL CENTERS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; GERMANY; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE;

EID: 80255141916     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.07.037     Document Type: Article

References (28)

1. E.J. Mills, B. Rachlis, C. O'Regan, L. Thabane, and D. Perri Metastatic renal cell cancer treatments: an indirect comparison meta-analysis BMC Cancer 9 2009 34
2. J.S. Thompson Coon, Z. Liu, and M. Hoyle Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness Br J Cancer 101 2009 238 243
3. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
4. B. Ljungberg, N.C. Cowan, and D.C. Hanbury EAU guidelines on renal cell carcinoma: the 2010 update Eur Urol 58 2010 398 406
5. R.J. Motzer, N. Agarwal, and C. Beard NCCN clinical practice guidelines in oncology: kidney cancer J Natl Compr Canc Netw 7 2009 618 630
6. G. Di Lorenzo, G. Carteni, and R. Autorino Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer J Clin Oncol 27 2009 4469 4474
7. Elfiky AA, Cho DC, McDermott DF, et al. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol. In press. DOI:10.1016/j.urolonc.2010.01.008.
8. C. Eichelberg, R. Heuer, and F.K. Chun Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis Eur Urol 54 2008 1373 1378
9. J.A. Garcia, T.E. Hutson, and P. Elson Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab Cancer 116 2010 5383 5390
10. M.P. Sablin, S. Negrier, and A. Ravaud Sequential sorafenib and sunitinib for renal cell carcinoma J Urol 182 2009 29 34 discussion 34
11. A.Z. Dudek, J. Zolnierek, A. Dham, B.R. Lindgren, and C. Szczylik Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 2009 61 67
12. E. Herrmann, N. Marschner, and M.O. Grimm Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma World J Urol 29 2011 361 366
13. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
14. R.J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol 17 1999 2530 2540 (Pubitemid 29368255)
15. M.M. Vickers, T.K. Choueiri, and M. Rogers Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy Urology 76 2010 430 434
16. G. Di Lorenzo, C. Buonerba, and P. Federico Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma Eur Urol 58 2010 906 911
17. Porta C, Procopio G, Carteni G, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. In press. DOI:10.1111/j.1464-410X.2011.10186.x.
18. Buchler T, Klapka R, Melichar B, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma - data from the Czech registry. Ann Oncol. In press.
19. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
20. G. Di Lorenzo, C. Porta, and J. Bellmunt Toxicities of targeted therapy and their management in kidney cancer Eur Urol 59 2011 526 540
21. N. Bhojani, C. Jeldres, and J.-J. Patard Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma Eur Urol 53 2008 917 930
22. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
23. T.E. Hutson, R.M. Bukowski, C.L. Cowey, R. Figlin, B. Escudier, and C.N. Sternberg Sequential use of targeted agents in the treatment of renal cell carcinoma Crit Rev Oncol Hematol 77 2010 48 62
24. G.R. Hudes Targeting mTOR in renal cell carcinoma Cancer 115(Suppl) 2009 2313 2320
25. I.N. Zama, T.E. Hutson, and P. Elson Sunitinib rechallenge in metastatic renal cell carcinoma patients Cancer 116 2010 5400 5406
26. S. Loges, M. Mazzone, P. Hohensinner, and P. Carmeliet Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited Cancer Cell 15 2009 167 170
27. J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
28. M. Paez-Ribes, E. Allen, and J. Hudock Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231